HINGHAM, Mass., Sept. 07, 2017 -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that Hezi Himelfarb, General Manager and Chief Operating Officer, is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 11, 2017 at 3:50 pm (ET) at the Lotte New York Palace in New York City.
A live webcast and subsequent archived replay of the Company’s presentation may be accessed via the ‘Investors’ section, under ‘Presentations and Resources’ of the Company’s website at www.microbotmedical.com.
About Microbot Medical, Inc.
Microbot, which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot’s current platforms, ViRob and TipCAT, are comprised of two highly advanced micro-robotic technologies, from which the Company is currently developing its first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures. Further information about Microbot Medical is available at http://www.microbotmedical.com.
The ViRob technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages as well as the ability to remain within the human body for prolonged time. To learn more about ViRob please visit http://www.microbotmedical.com/technology/virob/.
TipCAT is a transformational self-propelled, flexible, and semi-disposable endoscope providing see & treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT visit http://www.microbotmedical.com/technology/tipcat/.
Investor Contacts: EVC Group Michael Polyviou/Doug Sherk - Investors [email protected]; [email protected] 212-850-6020; 646-445-4800


Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 



